Table 1.
Baseline characteristics of patients.
| Characteristic | N (number of cases) = 10 |
|---|---|
| Age (yr) | 60 ± 7 |
| Male/female | 9/1 |
| CLTI wounds | 9 |
| Rutherford 5 | 6 |
| Rutherford 6 | 3 |
| Upper limb wound | 1 |
| Collagen disease (scleroderma) | 2 |
| Hypothyroidism | 2 |
| Catheter intervention | 9 |
| Bypass surgery | 0 |
| Chronic renal failure on hemodialysis | 8 |
| Hypertension | 4 |
| Diabetes mellitus | 7 |
| HbA1c% | 6.2 ± 1.0 |
| Hyperlipidemia | 3 |
| Smoking | 0 |
| Coronary artery disease | 7 |
| CABG surgery | 5 |
| EF% | 55.7 ± 16 |
| AF | 1 |
| Cerebral artery disease | 4 |
| Clopidogrel sulfate (ADP inhibitor) | 3 |
| Ethyl icosapentate (EPA) | 3 |
| Cilostazol | 3 |
| Aspirin | 7 |
| Limaprost alfadex (PGE1 derivative, prostanoid) | 1 |
| Atorvastatin (statin) | 2 |
| Pitavastatin (statin) | 1 |
| Warfarin | 5 |
| Carvedilol (αβ-blocker) | 3 |
| Sarpogrelate (5-HT2 antagonist) | 1 |
| Nifedipine (Ca channel blocker) | 1 |
Note: Total number of patients = 9; N (number of cases) = 10; cases 2 and 4 correspond to the same patient.
Abbreviations: AF, atrial fibrillation; CABG, coronary artery bypass grafting; CLTI, chronic limb-threatening ischemia; EF, ejection fraction; EPA, eicosapentaenoic acid; PGE1, prostaglandin E1.